PE20040412A1 - Compuestos triciclicos sustituidos como antagonistas de los receptores de trombina - Google Patents

Compuestos triciclicos sustituidos como antagonistas de los receptores de trombina

Info

Publication number
PE20040412A1
PE20040412A1 PE2003000375A PE2003000375A PE20040412A1 PE 20040412 A1 PE20040412 A1 PE 20040412A1 PE 2003000375 A PE2003000375 A PE 2003000375A PE 2003000375 A PE2003000375 A PE 2003000375A PE 20040412 A1 PE20040412 A1 PE 20040412A1
Authority
PE
Peru
Prior art keywords
link
het
absent
alkyl
antagonists
Prior art date
Application number
PE2003000375A
Other languages
English (en)
Inventor
Samuel Chackalamannil
Mariappan V Chelliah
Martin C Clasby
Enrico P Veltri
Yan Xia
Wenxue Wu
Yuguang Wang
William J Greenlee
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040412(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20040412A1 publication Critical patent/PE20040412A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

SE REFIERE A COMPUESTOS TRICICLICOS DE FORMULA I, DONDE LA LINEA PUNTEADA SIMPLE REPRESENTA UN ENLACE SIMPLE OPCIONAL; ......... REPRESENTA UN ENLACE DOBLE OPCIONAL; n ES 0 A 2; Q ES (a), (b), ENTRE OTROS; R1 Y R2 SON H, ALQUILO(C1-C6), MONO, DI, O TRI-FLUOROALQUIL-(C1-C6-)-, ALQUENILO(C2-C6), CICLOALQUILO(C3-C6), ENTRE OTROS; R3 ES H, OH, ALQUILO(C1-C6), ALCOXI(C1-C6), HALOGENO, -S0R16, ENTRE OTROS; Het ES UN HETEROARILO MONO O BI-CICLICO DE 5 A 10 ATOMOS CON 1 A 4 HETEROATOMOS DE N, O Y S, EN DONDE UN N DEL ANILLO PUEDE FORMAR UN N-OXIDO O GRUPO CUATERNARIO CON UN ALQUILO(C1-C4) Y Het PUEDE ESTAR UNIDO A B MEDIANTE UN C DEL ANILLO, DONDE Het ESTA SUSTITUIDO POR W; R8, R10 Y R11 SON R1 Y -OR1, SIEMPRE QUE EL DOBLE ENLACE ESTE PRESENTE, R10 ESTA AUSENTE; B ES -(CH2)n3, CIS O TRANS -(CH2)n4CR12=CR12a(CH2)n5- O -(CH2)n4CºC(CH2)n5-, DONDE n3 ES O A 5; n4 Y n5 SON O A 2; X ES -O- O -NR6- CUANDO LA LINEA REPRESENTA UN ENLACE SIMPLE O ES -OH O -NHR20 SI EL ENLACE ESTA AUSENTE; Y ES =O, =S, (H, H O OH) O (H, ALCOXI(C1-C6)), SI LA LINEA PUNTEADA ES ENLACE SIMPLE, O SI ESTA AUSENTE Y ES =O, ENTRE OTROS SUSTITUYENTES.ESTOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES DE TROMBINA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE TRANSTORNOS TROMBOTICOS, INFLAMATORIOS, ATEROSCLEROTICOS Y FIBROPROLIFERATIVOS. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS EN COMBINACION CON UN AGENTE CARDIOVASCULAR ADICIONAL COMO ASPIRINA O CLOPRIDROGEL
PE2003000375A 2002-04-16 2003-04-14 Compuestos triciclicos sustituidos como antagonistas de los receptores de trombina PE20040412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
PE20040412A1 true PE20040412A1 (es) 2004-07-12

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000375A PE20040412A1 (es) 2002-04-16 2003-04-14 Compuestos triciclicos sustituidos como antagonistas de los receptores de trombina

Country Status (34)

Country Link
US (3) US7304078B2 (es)
EP (5) EP1982984B1 (es)
JP (2) JP4558331B2 (es)
KR (1) KR101026929B1 (es)
CN (1) CN1659162B (es)
AR (1) AR039570A1 (es)
AT (3) ATE378330T1 (es)
AU (1) AU2003221932B2 (es)
BR (1) BRPI0309309B8 (es)
CA (1) CA2482858C (es)
CY (3) CY1107184T1 (es)
DE (3) DE60317493T3 (es)
DK (2) DK2065384T3 (es)
EC (1) ECSP045368A (es)
ES (3) ES2357876T3 (es)
FR (1) FR15C0047I2 (es)
HK (3) HK1070887A1 (es)
IL (1) IL164585A (es)
LT (1) LTC1495018I2 (es)
LU (1) LU92759I2 (es)
MX (1) MXPA04010308A (es)
MY (1) MY144040A (es)
NL (1) NL300746I2 (es)
NO (2) NO330500B1 (es)
NZ (2) NZ535880A (es)
PE (1) PE20040412A1 (es)
PL (1) PL214718B1 (es)
PT (2) PT2065384E (es)
RU (2) RU2329264C9 (es)
SG (1) SG164279A1 (es)
SI (2) SI2065384T1 (es)
TW (1) TWI343919B (es)
WO (1) WO2003089428A1 (es)
ZA (1) ZA200408342B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7442712B2 (en) * 2004-05-28 2008-10-28 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
EP1799243B1 (en) * 2004-10-06 2015-07-15 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
AR056262A1 (es) * 2005-01-14 2007-10-03 Schering Corp Preparacion de alcoholes propargilicos y esteres intermediarios de analogos de himbacina
DE602006020414D1 (en) * 2005-01-14 2011-04-14 Schering Corp Synthese von himbacinanaloga
CN101137636A (zh) * 2005-01-14 2008-03-05 先灵公司 Himbacine类似物的外型选择性合成
US7605275B2 (en) * 2005-01-14 2009-10-20 Schering Corporation Exo- and diastereo- selective syntheses of himbacine analogs
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
CA2601575A1 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
BRPI0620641A2 (pt) * 2005-12-22 2011-11-16 Schering Corp usos de compostos antagonistas de receptor de trombina na profilaxia de complicações de cirurgia cardiopulmonar
TW200812619A (en) * 2006-04-06 2008-03-16 Schering Corp TRA combination therapies
EP2007755B1 (en) 2006-04-13 2012-06-27 Schering Corporation Fused ring thrombin receptor antagonists
AU2007269830A1 (en) * 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US20080085923A1 (en) * 2006-10-04 2008-04-10 Schering Corporation Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine
CN101541782A (zh) 2006-10-04 2009-09-23 先灵公司 作为凝血酶受体拮抗剂的二环和三环衍生物
US20080194560A1 (en) * 2006-12-22 2008-08-14 Zhi Yun Wang Disintegration promoters in solid dose wet granulation formulations
US20080234236A1 (en) * 2007-03-23 2008-09-25 Veltri Enrico P Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
BRPI0907486A2 (pt) 2008-02-05 2015-07-14 Sanofi Aventis Triazolpiridazinas como inibidores de par1, sua produção e uso como medicamentos
NZ587142A (en) 2008-02-05 2012-04-27 Sanofi Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
EP2300435A2 (en) 2008-05-19 2011-03-30 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
DK2438060T3 (da) * 2009-06-04 2014-01-13 Merck Sharp & Dohme Aktiv metabolit af en trombin-receptor-antagonist
AU2010259003A1 (en) 2009-06-08 2011-11-10 Merck Sharp & Dohme Corp. A thrombin receptor antagonist and clopidogrel fixed dose tablet
AR077695A1 (es) 2009-08-04 2011-09-14 Schering Corp Derivados de pirimidina como inhibidores del factor ixa
EP2558462B1 (de) 2010-04-16 2014-10-22 Sanofi Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren
PL2558465T3 (pl) 2010-04-16 2015-05-29 Sanofi Sa Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1)
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US9604971B2 (en) 2013-07-22 2017-03-28 Aralez Pharmaceuticals Trading Dac Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
WO2015026693A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017181993A1 (zh) * 2016-04-22 2017-10-26 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CN116133660A (zh) 2020-07-22 2023-05-16 詹森药业有限公司 可用作因子XIa抑制剂的化合物
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
CN1290265A (zh) * 1997-11-25 2001-04-04 先灵公司 凝血酶受体拮抗剂
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
SK287026B6 (sk) 2000-06-15 2009-10-07 Schering Corporation Nor-seko-himbacínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7037920B2 (en) 2001-10-18 2006-05-02 Schering Corporation Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists

Also Published As

Publication number Publication date
HK1123302A1 (en) 2009-06-12
JP2005528406A (ja) 2005-09-22
LTC1495018I2 (lt) 2017-04-10
PL214718B1 (pl) 2013-09-30
DE60335679D1 (de) 2011-02-17
CA2482858A1 (en) 2003-10-30
NZ535880A (en) 2007-11-30
BRPI0309309B1 (pt) 2018-09-04
US20070179187A1 (en) 2007-08-02
PT1495018E (pt) 2008-02-19
NZ575139A (en) 2010-08-27
PL373332A1 (en) 2005-08-22
ZA200408342B (en) 2006-05-31
NO2015016I1 (no) 2015-07-20
EP1495018B1 (en) 2007-11-14
EP1495018B3 (en) 2011-03-16
ECSP045368A (es) 2005-01-03
CY1111363T1 (el) 2015-08-05
RU2329264C2 (ru) 2008-07-20
CY2015029I1 (el) 2016-04-13
ATE378330T1 (de) 2007-11-15
US20070270439A1 (en) 2007-11-22
EP1860106A1 (en) 2007-11-28
US7304078B2 (en) 2007-12-04
EP1982984A2 (en) 2008-10-22
IL164585A0 (en) 2005-12-18
TW200404068A (en) 2004-03-16
RU2329264C9 (ru) 2009-04-20
BR0309309A (pt) 2005-02-15
DE60317493D1 (en) 2011-01-13
CN1659162B (zh) 2011-08-31
EP1860106B1 (en) 2010-01-20
KR101026929B1 (ko) 2011-04-04
MXPA04010308A (es) 2005-02-03
WO2003089428A1 (en) 2003-10-30
AR039570A1 (es) 2005-02-23
EP2065384B1 (en) 2011-01-05
RU2004133375A (ru) 2005-07-10
DE60317493T2 (de) 2008-09-18
ATE455774T1 (de) 2010-02-15
US7713999B2 (en) 2010-05-11
EP2065384A1 (en) 2009-06-03
NL300746I1 (es) 2016-01-21
MY144040A (en) 2011-07-29
ES2357876T3 (es) 2011-05-03
NO2015016I2 (no) 2015-07-09
HK1129893A1 (en) 2009-12-11
ES2297150T3 (es) 2008-05-01
NO20044963L (no) 2004-11-15
EP2062890B1 (en) 2011-01-05
PT2065384E (pt) 2011-03-16
JP2010132710A (ja) 2010-06-17
IL164585A (en) 2010-11-30
LU92759I2 (en) 2015-08-31
RU2008106401A (ru) 2009-08-27
NL300746I2 (es) 2016-01-21
DE60317493T3 (de) 2018-07-12
CA2482858C (en) 2010-11-30
CY2015029I2 (el) 2016-04-13
ES2338171T3 (es) 2010-05-04
SI2065384T1 (sl) 2011-05-31
CN1659162A (zh) 2005-08-24
TWI343919B (en) 2011-06-21
EP2062890A1 (en) 2009-05-27
AU2003221932B2 (en) 2007-11-22
CY1107184T1 (el) 2012-10-24
SI1495018T1 (sl) 2008-04-30
NO330500B1 (no) 2011-05-02
DK2065384T3 (da) 2011-05-02
HK1070887A1 (en) 2005-06-30
JP4558331B2 (ja) 2010-10-06
KR20040099441A (ko) 2004-11-26
US20030216437A1 (en) 2003-11-20
SG164279A1 (en) 2010-09-29
EP1495018A1 (en) 2005-01-12
ATE494284T1 (de) 2011-01-15
FR15C0047I1 (es) 2015-08-28
FR15C0047I2 (fr) 2016-05-06
DE60331114D1 (de) 2010-03-11
BRPI0309309B8 (pt) 2021-05-25
AU2003221932A1 (en) 2003-11-03
ES2297150T7 (es) 2012-03-16
EP1982984B1 (en) 2013-02-13
EP1982984A3 (en) 2008-10-29
DK1495018T3 (da) 2008-02-18

Similar Documents

Publication Publication Date Title
PE20040412A1 (es) Compuestos triciclicos sustituidos como antagonistas de los receptores de trombina
PE20060957A1 (es) Compuestos pirazolopiridinas su preparacion y composiciones farmaceuticas
ECSP056097A (es) Antagonistas del receptor cgrp
AR067460A1 (es) Derivados de ftalazinona
CY1118805T1 (el) Νεες μορφες 5-αζακιτιδινης
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
UY28877A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida y composiciones
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20050013A1 (es) Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
AR056103A1 (es) Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
AR054789A1 (es) Antagonistas del receptor 1 de triazolopiridina canabinoide
PE20040832A1 (es) Derivados de indolil pirazinona
PE20090213A1 (es) Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
PE20040450A1 (es) Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
PE20060288A1 (es) Derivados de fenilaminopropanol
ECSP088638A (es) Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
PE20140102A1 (es) Compuestos de piperidina puenteada tipo quinoxalina sustituida con actividad sobre el receptor orl-1
PE20091732A1 (es) Dihidropirazolonas sustituidas y su uso
PE20070438A1 (es) Derivados de 4-fenil-pirimidina-6-sustituida-2-carbonitrilo como inhibidores de catepsina k y catepsina s

Legal Events

Date Code Title Description
FG Grant, registration